A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms
Latest Information Update: 31 Oct 2023
At a glance
- Drugs Cedazuridine/decitabine (Primary)
- Indications Chronic myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
- Focus Therapeutic Use
- 29 Sep 2021 Status changed from not yet recruiting to recruiting.
- 04 Aug 2021 New trial record